Molecules to Medicine with mTOR

Kenneth Maiese, MD, is an internationally recognized physician-scientist whose investigations are designed to translate basic science into successful therapeutic treatments. He maintains therapeutic and scientific expertise in multiple medical disciplines and has been fortunate to receive recognition with outstanding teaching and investigator awards, election to America’s Top Physicians and The Best of U.S. Physicians, recipient of Albert Nelson Marquis Lifetime Achievement Award, and elected as an America’s Health Insurance Plans (AHIP) Executive Leadership Fellow. His work has received the distinction of “High Impact Research and Potential Public Health Benefit” by the National Institutes of Health. As an internationally recognized physician researcher and “C-suite” healthcare leader, he has extensive experience in academic medicine, healthcare delivery, business development, managed care, biotechnology, and drug development holding positions as member and advisor for the National Institutes of Health Biotechnology and Venture Capital Development, National Institutes of Health Innovation Network, Chief Medical Officer, tenured Professor and Chair and Chief of Service of the Department of Neurology and Neurosciences of Rutgers University, Global Head of Translational Medicine and External Innovation, Board Member of the Cancer Institute of New Jersey, Steering Committee Member for the Foundation for the National Institutes of Health, tenured Professor in Neurology, Anatomy & Cell Biology, Molecular Medicine, the Barbara Ann Karmanos Cancer Institute, and the National Institute of Health Center at Wayne State University, and Founding Editor and Editor-in-Chief of multiple highly successful international journals.

• (1)  Novel Stem Cell Strategies with mTORKenneth Maiese(2)  mTOR: The master regulator of conceptus development in response to uterine histotroph during pregnancy in ungulatesXiaoqiu Wang, Guoyao Wu and Fuller W. Bazer(3)  mTORC1 in the control of myogenesis and adult skeletal muscle massMarita A. Wallace, David C. Hughes, and Keith Baar(4)  mTOR: A Critical Mediator of Articular Cartilage HomeostasisAkihiro Nakamura and Mohit Kapoor(5)  The Role of mTOR, Autophagy, Apoptosis and Oxidative Stress during Toxic Metal InjurySarmishtha Chatterjee, Chayan Munshi, and Shelley Bhattacharya Section II.  mTOR in Genetic Disorders and Neurodegenerative Disease(6)  The mTOR signaling pathway in neurodegenerative diseasesArnaud FRANCOIS, Julie VERITE, Agnès RIOUX BILAN, Thierry JANET, Frédéric CALON, Bernard FAUCONNEAU, Marc PACCALIN, and Guylène PAGE(7)  mTOR: Exploring a new potential therapeutic target for strokeMar Castellanos, Carme Gubern, and Elisabet Kadar (8) mTOR signalling in epilepsy and epileptogenesis: preclinical and clinical studiesAntonio Leo, Andrew Constanti, Antonietta Coppola, Rita Citraro, Giovambattista De Sarro, and Emilio Russo(9)  mTOR, Autophagy, Aminoacidopathies and Human Genetic DisordersGarrett R. Ainslie, K. Michael Gibson, and Kara R. Vogel Section III.  mTOR in Memory, Behavior, and Aging(10)  mTOR involvement in the mechanisms of memory: an overview of animal studiesMaria Grazia Giovannini and Daniele Lana(11)  Mammalian Target of Rapamycin (mTOR), Aging, Neuroscience And Their Association With Aging-Related DiseasesErgul Dilan Celebi Birand, Elif Tugce Karoglu, Fusun Doldur Balli, and Michelle Adams(12)  The role of mTOR in mood disorders pathophysiology and treatmentGislaine Z. Réus, Meagan R. Pitcher, Camila O. Arent, and João Quevedo(13)  mTOR and Drugs of AbuseJacob T. Beckley and Dorit Ron Section IV.  mTOR in Cardiovascular Development and Disease (14)  mTOR as a modulator of metabolite sensing relevant to angiogenesisSoumya S.J., Athira A.P., Binu S. and  Sudhakaran P. R(15)  Role of mTOR Signaling in CardioprotectionAnindita Das and Rakesh C Kukreja(16)  Role of Mammalian Target of Rapamycin (mTOR) in Cardiac Homeostasis in Metabolic DisordersXiangwei Liu and Jun Ren Section V.  mTOR in the Immune System and Autoimmune Disorders(17)  Roles of Mechanistic Target of Rapamycin in the Adaptive and Innate Immune SystemsHiroshi Kato and Andras Perl (18)  The Role of mTOR Inhibitors in Solid Organ TransplantationGreg J. McKenna and Goran B.G Klintmalm(19)  mTOR and neuroinflammationFilipe Palavra, António Francisco Ambrósio, and Flávio Reis(20)  Novel Molecular targets in Multiple Sclerosis: the emerging role of mTOR in the regulation of glial biologyCinzia Dello Russo, Pierluigi Navarra, and Lucia Lisi Section VI.  mTOR in the Endocrine System and Disorders of Metabolism(21)  mTOR in metabolic and endocrine disordersMarta M. Swierczynska and Michael N. Hall(22)  Chronic mTOR inhibition by rapamycin and diabetes: What is the role of mitochondria?Liang-Jun Yan and Zhiyou Cai(23)  mTOR in diabetic nephropathy and retinopathyRosa Fernandes and Flávio Reis Section VII.  mTOR and Cancer(24)  Lymphangioleiomyomatosis (LAM): Molecular Insights into mTOR Regulation Lead to Targeted Therapies Wendy K. Steagall, Connie G. Glasgow, Gustavo Pacheco-Rodriguez, and Joel Moss(25)  mTOR PATHWAY IN RENAL CELL CARCINOMAMatteo Santoni and Francesco Massari(26)  Metabolic Shunt Pathways, Carcinoma, and mTORNorisuke Shibuya, Ken-ichi Inoue, and Keiichi Kubota

Select Guide Rating